The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 17407040.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The Clinical and Laboratory Standards Institute (formerly, the NCCLS) established the susceptibility and resistance breakpoints for minimal inhibitory concentration (MIC) and disk diffusion testing of vancomycin against isolates of Staphylococcus aureus > 20 years ago. The disk diffusion breakpoints were modified in 1998 when it was recognized that vancomycin-intermediate S. aureus strains were not detected by this method. In 2006, the vancomycin MIC breakpoints for S. aureus were lowered (from < or = 4 microg/mL to < or = 2 microg/mL for "susceptible," from 8-16 microg/mL to 4-8 microg/mL for "intermediate," and from > or = 32 microg/mL to > or = 16 microg/mL for "resistant") to increase detection of heterogeneously resistant isolates of S. aureus. This decision reflected a growing amount of microbiological and clinical data indicating that isolates of S. aureus are less likely to respond to vancomycin therapy when the vancomycin MICs are > or = 4 microg/mL.
Medical subject headings
- Anti-Bacterial Agents
- Staphylococcus aureus
- Vancomycin